inHEART will also use the fund to support its commercial development in Europe and to foray into the US market. Credit: Luke MacQueen and Michael Rosnach, Harvard University.

France-based inHEART has secured additional funding to support the development of artificial intelligence (AI), medical imaging and numerical simulations of cardiac arrhythmias.

The company has raised $4.2m in a financing round led by Elaia, a venture capital company focused on European digital and deep-tech startups.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

inHEART plans to use the proceeds to accelerate its commercial development in Europe and to foray into the US market.

inHEART CEO and co-founder Jean-Marc Peyrat said: “We are very happy to have Elaia joining inHEART in this adventure not only for its financial support but also for the dynamism and the expertise of its team in developing startups in healthcare.

“Elaia and inHEART share the same ambition to create a major player in cardiac electrophysiology, a €5bn market with healthcare giants such as Johnson & Johnson, Abbott, Boston Scientific or Medtronic.”

The company offers a Cloud-based software solution that converts preoperative medical images into a 3D digital twin of the patient’s heart.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It allows the cardiologist to better plan the procedure and assists in navigating instruments in the patient’s heart. The solution reduces procedure duration and failure rates considerably.

Existing treatment solutions for patients with arrhythmia are not optimal, whether considering drugs, implantable devices or even catheter ablation procedures, the company noted.

Approximately 40% of the patients with ventricular arrhythmias undergo a repeat procedure due to recurrence.

The company is a spin-off from IHU Liryc, which specialises in cardiac electrophysiology, and Inria, a digital science and technology company.

It was founded by an experienced team of scientists and physicians, including AI and cardiac modelling expert MaximeSermesant, radiologist Hubert Cochet and cardiologist Pierre Jaïs.